PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Brian Silver joins Perella Weinberg Partners as partner

Brian Silver has joined Perella Weinberg Partners as a partner in the firm’s advisory business with a focus on clients in the healthcare sector.

 
Silver has approximately 20 years of investment banking and corporate legal experience. He was most recently a managing director in Morgan Stanley’s healthcare investment banking group, where he advised a broad range of biopharmaceutical and pharmaceutical services clients on mergers and acquisitions, initial public offerings, the equity and debt capital markets, and royalty financing.
 
During his tenure at Morgan Stanley, Silver advised on a number of significant transactions, including Mylan’s USD1.6bn acquisition of Agila Specialties Private Limited; Quintiles Transnational’s USD1.1bn initial public offering; The Carlyle Group and Hellman & Friedman’s USD3.9bn acquisition of Pharmaceutical Product Development; three landmark financings totalling USD320m for Synageva Biopharma; and New York University’s sale of its worldwide royalty interest in Remicade to Royalty Pharma for USD650m.
 
Silver joins a global team of six healthcare sector advisory professionals led by partners Christopher O’Connor and Philippe McAuliffe in New York, and managing director Nick Johnston in London.
 
Peter Weinberg, a founding partner and head of advisory at Perella Weinberg Partners, says: “Attracting high-calibre talent in areas where we believe we can have meaningful impact and where we can provide world-class advice is a primary focus for the firm. Adding Brian to our team illustrates this continued approach and enhances our coverage of the healthcare sector. His broad pharmaceutical and healthcare industry experience complements our existing capabilities and allows us to advise clients across a greater segment of the healthcare sector.”
 
Silver says: “Perella Weinberg Partners is a highly-respected independent advisory firm, with a significant commitment and track record in healthcare investment banking. I am excited to join their experienced team to further expand coverage of the biopharmaceutical and pharmaceutical services sectors. Commercial and regulatory changes in the healthcare industry are driving high levels of strategic activity and significant evolution of business models. I look forward to working with my new colleagues to help our clients navigate these challenges.”

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured